Navigation Links
PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
Date:2/1/2012

ates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which "Ri
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
4. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
5. PAREXEL Ranks as a "Best 5 Outsourcing Company for the Pharmaceutical Industry" by IAOP®
6. PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM)
7. PAREXEL International to Present at Wells Fargo Healthcare Conference
8. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
9. PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
11. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 ... released today including improvements to the enterprise replication ... connectors for Lucene, SOLR and Elasticsearch. This release ... this high performance triplestore – GraphDB™ was formerly ... in deploying the only mature enterprise resilient RDF ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has ... (SOFCs) - Global Strategic Business Report" report to their ... for Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The ... Canada , Europe , ... forecasts are provided for the period 2012 through 2020. Market ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... SAN DIEGO and ST. LOUIS, June 27, 2011 ... industrial biotechnology company focused on the development and commercialization ... manufacturer of animal and human nutrition and health products, ... commercialize a suite of new enzyme products from Verenium,s ...
... of our nation,s long-term clean-energy future, but the technology ... Japan,s recent Fukushima disaster. Indeed, many nations have called ... are operating safely. In the United States, ... percent of the electricity from emission-free sources, including renewable ...
... France, June 24, 2011 Mediabrands, IPG Media ... Lions International Advertising Festival, the results of the ... MIT, Affectiva is able to record and measure ... correlating to an individual,s facial features are established ...
Cached Biology Technology:Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 2Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 3Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 4Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 5Berkeley scientists pioneer nanoscale nuclear materials testing capability 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... sweet and salty aroma of sunscreen and seawater signals ... now reporting that the idyllic beach vacation comes with ... skin and into the sea, they can become toxic ... the main course for many other marine animals. Their ... & Technology . , Antonio Tovar-Sanchez and David Snchez-Quiles ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... is available in German . , ... has developed a model, which identifies potential habitats and corridors ... Rheinland-Pfalz as an example, it was demonstrated that almost half ... enabling a maximum population of 1600 females. The model can ...
... is a link between alcohol consumption and increased risk of ... 5,870 young adult women. The study, published in ... found that the risk increased 3% for every additional alcoholic ... observe any increase in risk of seasonal allergic rhinitis according ...
... Achieves record biometric revenues and profitability, WALL, ... Board: BKYI), a leader in wireless public safety ... profitability and strong revenue growth for its second ... continuing operations for the quarter ended June 30,2008 ...
Cached Biology News:Let the cat keep chasing the mouse 2Let the cat keep chasing the mouse 3Let the cat keep chasing the mouse 4Alcohol is associated with risk of perennial allergic rhinitis 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 4BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 5
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... is a sample preparation kit for reduction ... of detergents, phenolic compounds, salts, and most ... samples. The kit procedure involves a TCA-like ... or cells, plant leaves, E. coli, and ...
... Myosin II Heavy Chain Isoform B ... + 0.03% Thimerosal) This antibody was ... to the C-terminus of nonmuscle myosin ... antibody is effective in immunoblotting and ...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
Biology Products: